Diabetes

Researchers and Allegheny County plan a $13.3 million trial of weekly semaglutide to reduce opioid and alcohol use and justice involvement.

Insulin analogue cost-effectiveness studies for adults with type 1 diabetes mostly point the same way: the newer products usually come out ahead of human insulin. A new systematic review says that headline rests on thinner ground than it looks. The paper, by Shiwa Yaghoubi Bina, Steve Njokuocha and the T1D Economic Evidence Synthesis Group, has been accepted for Value in Health. The version available now is a pre-proof, so figures could still change at copyediting. The World Health Organization funded […]

Zorginstituut Nederland has ruled that the Inreda AP stays out of the Dutch basic package. The DARE trial found no clinically relevant gain in glucose control or quality of life, serious adverse events were about three times more common, and half of the patients stopped using the device. #SyenzaNews #MedTech #MarketAccess #HealthEconomics

Eli Lilly and Company has set a parity target for its diabetes and obesity medicines: treat as many people in low- and middle-income countries as in high-income countries by 2040. The commitment carries no price mechanism, so progress will be judged against Lilly's own annual Sustainability Report. #SyenzaNews #globalhealth #pharmaceuticals #MarketAccess

Sweden's pharmaceutical injury insurance logged 33 semaglutide adverse reactions claims in the first eight months of 2026, up from 13 in all of 2025. More prescribing and more awareness explain the rise better than any new risk. #SyenzaNews #pharmaceuticals #drugsafety #regulatoryaffairs

FDA approved finerenone (Kerendia) for CKD associated with type 1 diabetes, the first new treatment for this population in 30 years. The label rests on a six-month UACR reduction, not hard kidney outcomes, so payers and HTA agencies will each have to decide how much credit the surrogate deserves. #SyenzaNews #MarketAccess #CKD #Type1Diabetes

Novo Nordisk and Anthropic have announced a partnership to speed drug discovery. Novo will use Claude Science across R&D and for agentic software engineering, with robust data governance and human oversight built in. #SyenzaNews #DrugDiscovery #AI #MarketAccess

Novo Nordisk rebrands to Novo and drops the dual name as obesity shifts to a consumer market. What changes, what is left behind, and what the 21 September Capital Markets Day must deliver. #SyenzaNews #NovoNordisk #MarketAccess #Obesity

Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica

The FDA has cleared Abbott's Libre Duo 10 Day, the first continuous glucose ketone monitor that tracks ketones and glucose every minute to flag diabetic ketoacidosis risk before it becomes an emergency. #SyenzaNews #Diabetes #MedicalDevices #MarketAccess

Is tirzepatide delivering better value than semaglutide for patients and payers? A fresh analysis shows how tirzepatide can drive greater cost savings alongside improved health outcomes in obesity and type 2 diabetes management. Discover the key findings shaping treatment and reimbursement decisions. #SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness

🚀 What if the first oral GLP-1 therapy just cleared its biggest regulatory hurdle in Europe? The MHRA has approved orforglipron, delivering the continent’s first oral win and offering patients a convenient, needle-free option for weight management and type 2 diabetes. Read the full story on this landmark approval. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess